Actively Recruiting
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.
CONDITIONS
Official Title
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (≥ 18 years old)
- With confirmed cystic fibrosis
- Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center
You will not qualify if you...
- Patients who have undergone a double lung transplant for cystic fibrosis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Pneumologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
R
Romain Kessler, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here